Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant

Bibliography

• Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Moss SE, et al. The wisconsin epidemiologic study of diabetic retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 1995;102(1):7-16
   PubMed Web of Science ®Google Scholar
• Ferris FL III, Patz A. Macular edema. A complication of diabetic retinopathy. Surv Ophthalmol 1984;28(Suppl):452-61
   PubMed Web of Science ®Google Scholar
• ETDRS Research Group.Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Arch Ophthalmol 1985;103(12):1796-806
   PubMedGoogle Scholar
• Miller JW, Le Couter J, Strauss EC, et al. Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology 2013;120(1):106-14
   PubMed Web of Science ®Google Scholar
• Boyer DS, Hopkins JJ, Sorof J, et al. Anti-vascular endothelial growth factor therapy for diabetic macular edema. Ther Adv Endocrinol Metab 2013;4(6):151-69
   PubMedGoogle Scholar
• Crum R, Szabo S, Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 1985;230(4732):1375-8
   PubMedGoogle Scholar
• Oliver A, Ciulla TA. Corticosteroids as antiangiogenic agents. Ophthalmol Clin North Am 2006;19(3):345-51; v
   PubMedGoogle Scholar
• Edelman JL. Differentiating intraocular glucocorticoids. Ophthalmologica 2010;224(Suppl 1):25-30
   PubMed Web of Science ®Google Scholar
• Tokida Y, Aratani Y, Morita A, et al. Production of two variant laminin forms by endothelial cells and shift of their relative levels by angiostatic steroids. J Biol Chem 1990;265(30):18123-9
   PubMed Web of Science ®Google Scholar
• Ingber DE, Madri JA, Folkman J. A possible mechanism for inhibition of angiogenesis by angiostatic steroids: induction of capillary basement membrane dissolution. Endocrinology 1986;119(4):1768-75
   PubMedGoogle Scholar
• Stokes CL, Weisz PB, Williams SK, et al. Inhibition of microvascular endothelial cell migration by beta-cyclodextrin tetradecasulfate and hydrocortisone. Microvas Res 1990;40(2):279-84
   PubMedGoogle Scholar
• Wang YS, Friedrichs U, Eichler W, et al. Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells. Graefes Arch Clin Exp Ophthalmol 2002;240(1):42-8
   PubMedGoogle Scholar
• Jonas J, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 2001;132:425-7
   PubMed Web of Science ®Google Scholar
• Jonas J, Degenring R. Intravitreal injection of crystalline triamcinolone acetonide in the treatment of diffuse diabetic macular oedema. Klin Monatsbl Augenheilkd 2002;219:429-32
   PubMed Web of Science ®Google Scholar
• Jonas J, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 2003;87:24-7
   PubMed Web of Science ®Google Scholar
• Martidis A, Duker J, Greenberg P, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002;109:920-7
   PubMed Web of Science ®Google Scholar
• Massin P, Audren F, Haouchine B, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 2004;111:218-25
   PubMed Web of Science ®Google Scholar
• Audren F, Erginay A, Haouchine B, et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial. Acta Ophthalmol Scand 2006;84(5):624-30
   PubMedGoogle Scholar
• Elman MJ, Bressler NM, Qin H, et al. Diabetic Retinopathy Clinical Research Network. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011;118(4):609-14
   PubMed Web of Science ®Google Scholar
• Beer PM, Bakri SJ, Singh RJ, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 2003;110(4):681-6
   PubMed Web of Science ®Google Scholar
• Callanan DG, Gupta S, Boyer DS, et al. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology 2013;120(9):1843-51
   PubMed Web of Science ®Google Scholar
• Pacella E, Vestri AR, Muscella R, et al. Preliminary results of an intravitreal dexamethasone implant (Ozurdex(R)) in patients with persistent diabetic macular edema. Clin Ophthalmol 2013;7:1423-8
   PubMedGoogle Scholar
• Boyer DS, Faber D, Gupta S, et al. Ozurdex CHAMPLAIN Study Group. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 2011;31(5):915-23
   PubMed Web of Science ®Google Scholar
• Pearson PA, Comstock TL, Ip M, et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology 2011;118(8):1580-7
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Hafiz G, Shah SM, et al.; Famous Study Group. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology 2010;117(7):1393-9
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012;119(10):2125-32
   PubMed Web of Science ®Google Scholar
• Razeghinejad M, Katz L. Steroid-induced iatrogenic glaucoma. Ophthalmic Res 2012;47:66-80
   PubMed Web of Science ®Google Scholar
• Spiers F. Topical steroids and intraocular pressure. II. An evaluation of the intraocular pressure in 93 outpatients divided according to their response to monocular steroid provocation and studies on the reaction of the control eye. Acta Ophthalmol (Copenh) 1965;43(6):812-20
   PubMedGoogle Scholar
• Tektas OY, Lutjen-Drecoll E. Structural changes of the trabecular meshwork in different kinds of glaucoma. Exp Eye Res 2009;88(4):769-75
   PubMed Web of Science ®Google Scholar
• Wordinger RJ, Clarka AF. Effects of glucocorticoids on the trabecular meshwork: towards a better understanding of glaucoma. Prog Retin Eye Res 1999;18(5):629-67
   PubMed Web of Science ®Google Scholar
• Arcinue CA, Ceron OM, Foster CS. A comparison between the fluocinolone acetonide (retisert) and dexamethasone (ozurdex) intravitreal implants in uveitis. J Ocul Pharmacol Ther 2013;29(5):501-7
   PubMed Web of Science ®Google Scholar
• Bollinger K, Kim J, Lowder CY, et al. Intraocular pressure outcome of patients with fluocinolone acetonide intravitreal implant for noninfectious uveitis. Ophthalmology 2011;118(10):1927-31
   PubMedGoogle Scholar
• Mataftsi A, Dabbagh A, Moore W, et al. Evaluation of whether intracameral dexamethasone predisposes to glaucoma after pediatric cataract surgery. J Cataract Refract Surg 2012;38(10):1719-23
   PubMed Web of Science ®Google Scholar
• Kiddee W, Trope GE, Sheng L, et al. Intraocular pressure monitoring post intravitreal steroids: a systematic review. Surv Ophthalmol 2013;58(4):291-310
   PubMedGoogle Scholar